Due To The Current Limitations With Travel From China The “China Clinical Development Partnering Forum” is Postponed

The SCOPE China Clinical Development Partnering Forum

Tuesday: February 18, 2020 from 2:00 to 5:00 pm at CHI’s SCOPE Summit in Orlando

The new China Partnering Forum at SCOPE provides a focused forum where Global and Chinese-based pharmaceutical companies, biotech companies, academic research centers, CROs, consultancies and other service providers involved in the conduct of drug development and clinical trials can share best practices for developing and bringing new therapies to market here in the West and in China. The stakeholders may be US or European sponsors interested in partnering with up-and-coming Chinese biotech companies, or they may be Chinese innovators looking for US-based CROs or licensing partners to expand their market and reach. This is not simply about “outsourcing”! This is about research-based innovators on both sides trying to figure out a win-win and trying to help one another navigate a two-way partnership. The forum will feature case studies, “how to” panel discussions, and networking. The atmosphere will be casual and interactive, though the topic is very important and somewhat complicated at this moment in time. Speaking proposals and panel proposals are being accepted, but they must include actual best practices and leaders who can offer accurate advice on how best to find partners on both sides.

新的SCOPE中国伙伴论坛将在2020年二月18日在美国佛罗里达州欧伦达市（Orlando, FL, USA）举行。这个论坛是2020 SCOPE年会的一部分，它的目的是为全球和中国的药物企业，生物公司，研究中心，CRO， 和其他的药物研发和临床试验的服务公司提供一个好的场合来分享它们在从药物开发到在东、西方国家及中国上市的成功经验。目前很多美国及欧洲的药企非常感兴趣与中国的企业及CRO建立合作伙伴关系。这不仅仅是“外包”，它也是东、西方药物研究创新者们试图找出互相帮助的双赢方法的尝试。从另外的一个角度，中国的企业也希望与美国及其他的西方国家的公司、企业、和研究机构建立合作关系，以将中国的药物及研发工作扩展到美国或其他西方国家。这个论坛将利用一些实例和专家讨论帮助参加者建立广泛关系网。 论坛将是一个非正式的交流场合。希望您或您的公司能够参加这个论坛。论坛现在已经开放接受讲演者和论坛讨论者，如果您希望分享您的成功经验及开展东西方合作的心得，请同组织者直接联系。

REGISTER NOW TO ATTEND SCOPE 2020 &
SCOPE China Clinical Development Partnering Forum
www.scopesummit.com/pre-conference-forum-form

Attendees must be registered as a “Best Value” SCOPE conference participant (using discount code CHINA).
If you would like to attend, please save your seat by registering with Melissa Dolen at mdolen@healthtech.com or (+1) 781-972-5418 or online at https://register.healthtech.com/reg?SCO20&ID=19798&CO=0

PROGRAM COMMITTEE & FACULTY

Jane Fang, MD, MS, Director, Leader of Digital Clinical Innovations, RWD/RWE for Clinical Trials, AstraZeneca

Sean Zhao, PhD, Head, US Patient Safety, AstraZeneca

Yue Yang, PhD, Director, International Center for Food and Drug Policy and Legal Research, Shenyang Pharmaceutical University

Amanda Fu, MD, MBA, Founder and CEO, RedBud Pharma

Walt Cao, PhD, President, Zeta Therapeutics, Inc.

Micah Lieberman, Executive Director, Conferences, Cambridge Healthtech Institute (CHI)

Marina Filshtinsky, MD, Executive Director, Conferences, Cambridge Healthtech Institute (CHI)

Dan Zhang, CEO, Fountain Medical Development Ltd.

Chuck Bradley, Vice President, Clinical Development, FibroGen, Inc.

Xiaoyao Conny Mo, MD, Partner, Lead of Medical Safety Consulting, Beijing Renheguangtong (RHGT) Co., Ltd.

Wendy Wang, PhD, MD, Managing Director, Linical Accelovance Group

AGENDA

Tuesday: February 18, 2020 from 2:00 to 5:00 pm

CHINESE PHARMA INDUSTRY CHALLENGES AND OPPORTUNITIES & NEW CHINESE DRUG DEV REGULATIONS

1:30 pm Registration

2:00  Organizers’ Welcome
Micah Lieberman, Executive Director, Conferences, Cambridge Healthtech Institute (CHI)
Marina Filshtinsky, MD, Executive Director, Conferences, Cambridge Healthtech Institute (CHI)

2:05  Chinese Pharmaceutic Industry and Its Future Direction: Challenges and Opportunities
Walt Cao, PhD, President, Zeta Therapeutics,Inc.

2:25  China R&D Innovation Strategy under New Drug Development and Regulatory Environment: The Newly Passed Drug Administration Law of the People’s Republic of China
Yue Yang, PhD, Director, International Center for Food and Drug Policy and Legal Research, Shenyang Pharmaceutical University

CONDUCTING TRIALS IN CHINA & COMPARE AND CONTRAST HOW CROS IN CHINA & US OPERATE IN DRUG DEVELOPMENT

2:45  Opportunities and Challenges of Conducting Clinical Trials in China (vs North America and Europe)
Amanda Fu, MD, MBA, Founder and CEO, RedBud Pharma

3:05  Panel Discussion: Compare/Contrast CROs in China & CROs in US – How We Operate in Drug Development

Moderator: Jane Fang, MD, MS, Director, Leader of Digital Clinical Innovations, RWD/RWE for Clinical Trials, AstraZeneca

Dan Zhang, CEO, Fountain Medical Development Ltd.

Amanda Fu, MD, MBA, Founder and CEO, RedBud Pharma

Yue Yang, PhD, Director, International Center for Food and Drug Policy and Legal Research, Shenyang Pharmaceutical University

3:35  Networking Break

US-CHINA INDs and NDAs & ESTABLISHING CHINA-US ALLIANCES

4:05  US-China Comparison on IND, NDA and Conduct of Clinical Trials
Dan Zhang, MD, Executive Chairman, Fountain Medical Development Ltd.

4:20  Panel Discussion: How to Establish China and US Collaborative Alliance in Drug Development

Moderator: Wendy Wang, PhD, MD, Managing Director, Linical Accelovance Group

Walt Cao, PhD, President, Zeta Therapeutics, Inc.

Chuck Bradley, Vice President, Clinical Development, FibroGen, Inc.

Xiaoyao Conny Mo, MD, Partner, Lead of Medical Safety Consulting, Beijing Renheguangtong (RHGT) Co., Ltd. 

4:50  Chairperson’s Closing Remarks: Next Steps for Chinese, US, European and RoW Life Sci Companies to Further Partnerships in and with China
Jane Fang, MD, MS, Director, Leader of Digital Clinical Innovations, RWD/RWE for Clinical Trials, AstraZeneca

4:55  China Forum Ends, Transition to SCOPE Evening Keynote and Happy Hour

JOIN THE KICK-OFF KEYNOTE, PARTICIPANT ENGAGEMENT AWARD & HAPPY HOUR

www.scopesummit.com/keynotes

5:00 Evening Plenary Keynote Opening Remarks
Matt Miller, President, Co-Founder, StudyKIK
Micah Lieberman, Executive Director, Conferences, Cambridge Healthtech Institute (CHI)

5:05 INTERACTIVE PANEL: Taking the Plunge, Why Now is the Time to Invest in eConsent and Patient Engagement
Moderator: Bill Byrom, Vice President, Product Strategy and Innovation, Signant Health

5:40 SCOPE’s 2020 Participant Engagement Awards Introduction

Joseph Kim, MBA, Senior Advisor, Patient Experience and Design Innovation, Eli Lilly

6:20 SCOPE’S Kick-Off Networking Happy Hour    (Co-Sponsorship Opportunities Available)

7:30 Close of day (SCOPE Continues Wednesday, Thursday, Friday: www.scopesummit.com )

REGISTER NOW TO ATTEND SCOPE 2020 &
SCOPE China Clinical Development Partnering Forum
www.scopesummit.com/pre-conference-forum-form

Attendees must be registered as a “Best Value” SCOPE conference participant (using discount code CHINA).
If you would like to attend, please save your seat by registering with Melissa Dolen at mdolen@healthtech.com or (+1) 781-972-5418 or online at https://register.healthtech.com/reg?SCO20&ID=19798&CO=0

Key Contacts

About SCOPE:
Celebrating its 11th successful year, SCOPE Summit 2020 takes place February 18-21 in Orlando, FL. SCOPE attracted more than 2,200 leaders in clinical operations and research in 2019 and we are expecting record attendance in 2020. Over the course of four stimulating days of in-depth discussions in 20 different conferences, 3 plenary keynote sessions, the annual Participant Engagement Awards, and the ever-popular interactive breakout discussions, the programming focuses on advances and innovative solutions in all aspects of clinical trial planning, management and operations, including: Site Selection and Management, Patient Engagement, Recruitment and Retention, Protocol Optimization, Feasibility, Data Strategy and Analytics, Sensors and Wearables, Project Management, Outsourcing, Forecasting, Budgeting and Contracting, Resource Management, Quality (QbD) in Trial Conduct, Risk-Based Monitoring, Artificial Intelligence, Post-Marketing Studies, Observational Research, Accessing and Generating RWD, Clinical Biomarker Strategy, Clinical Supply Chain, Precision Medicine, Clinical Biomarkers and Biospecimens, and Central Lab Solutions, and an all new track on Medical Device Clinical Trial Operations and Regulations. SCOPE is brought to you by Cambridge Innovation Institute (CII) and Cambridge Healthtech Institute (CHI), the organizers of Bio-IT World, AI World, Next Generation Diagnostics, PEGS, PepTalk, Discovery on Target and other events.

SCOPE 2019 attracts record attendance with more than 2,000 participants

A Leader in the Clinical Trial Industry: SCOPE Grows by 20% for the fourth consecutive year

2019 Event Features

• 2,000+ participants
• 19 conferences
• Participant Engagement Awards
• Dedicated Exhibit Hall Hours & Networking Functions
• Interactive Breakout Discussions
• Greater Gift Vaccine Dontations

SUBMIT YOUR SCOPE China Clinical Development Partnering Forum PROPOSAL!!!

The impressive executive audience at SCOPE came together for invaluable networking opportunities with more than 52% of the attendees titled as a decision maker from leading Pharma (20%), CRO (35%), and Biotech companies (20%). Industry leaders and key decision makers representing 28 different countries and more than 700 unique organizations shared case studies, collaborated on best practices and provided unique perspectives on poignant issues that the field currently faces.

2019 Attendee Demographics